Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mauro Passucci

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Frontiers in Oncology|June 23, 2023
Case Report: Avelumab and ruxolitinib to manage polycythemia vera and secondary metastatic Merkel cell carcinoma: a possible successful combinationChiara Masucci, Mauro Passucci, Emilia Scalzulli, et al.
Expert Opinion on Emerging Drugs|May 31, 2023
Systemic mastocytosis: 2023 update on diagnosis and management in adultsAlessandro Costa, Emilia Scalzulli, Ida Carmosino, et al.
Mediterranean Journal of Hematology and Infectious Diseases|March 12, 2024
Secondary Prophylaxis of Venous Thromboembolism (VTE) with Low Dose Apixaban or Rivaroxaban: Results from a Patient Population with More than 2 Years of Median Follow-upAlessandro Laganà, Giovanni Manfredi Assanto, Chiara Masucci, et al.
Journal of Clinical Apheresis|January 18, 2021
Early response to caplacizumab and rituximab after anaphylaxis to Octaplas plasma in a patient with thrombotic thrombocytopenic purpuraSalvatore Perrone, Mauro Passucci, Elettra Ortu La Barbera, et al.
Frontiers in Oncology|May 17, 2023
Case Report: Infectious prophylaxis in hematological malignanciesMauro Passucci, Chiara Masucci, Francesca Paoletti, et al.
Nuclear Medicine and Molecular Imaging|October 22, 2020
Acute Promyelocytic Leukemia After Radium-223 Exposure for Prostate Cancer in a Chemotherapy-Naïve PatientSalvatore Perrone, Elettra Ortu La Barbera, Tiziana Ottone, et al.
European Journal of Haematology|February 9, 2024
Neutrophil to lymphocyte ratio in myelofibrosis patients treated with ruxolitinib may predict prognosis and rate of discontinuationAlessandro Laganà, Mauro Passucci, Sara Pepe, et al.
Leukemia & Lymphoma|July 12, 2023
<i>CCND2</i> mutations in atypical chronic myeloid leukemia: a report of two casesGiovanni Iaquinta, Emilia Scalzulli, Silvia Angeloni, et al.
British Journal of Haematology|February 21, 2026
Prognostic impact of treatment-related and geriatric factors in older patients with classic Hodgkin lymphoma: A real-life cohort studySilvio Ligia, Giovanni Manfredi Assanto, Tania Soriano, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Frontiers in Oncology|June 23, 2023
Case Report: Avelumab and ruxolitinib to manage polycythemia vera and secondary metastatic Merkel cell carcinoma: a possible successful combinationChiara Masucci, Mauro Passucci, Emilia Scalzulli, et al.
Expert Opinion on Emerging Drugs|May 31, 2023
Systemic mastocytosis: 2023 update on diagnosis and management in adultsAlessandro Costa, Emilia Scalzulli, Ida Carmosino, et al.
Mediterranean Journal of Hematology and Infectious Diseases|March 12, 2024
Secondary Prophylaxis of Venous Thromboembolism (VTE) with Low Dose Apixaban or Rivaroxaban: Results from a Patient Population with More than 2 Years of Median Follow-upAlessandro Laganà, Giovanni Manfredi Assanto, Chiara Masucci, et al.
Journal of Clinical Apheresis|January 18, 2021
Early response to caplacizumab and rituximab after anaphylaxis to Octaplas plasma in a patient with thrombotic thrombocytopenic purpuraSalvatore Perrone, Mauro Passucci, Elettra Ortu La Barbera, et al.
Frontiers in Oncology|May 17, 2023
Case Report: Infectious prophylaxis in hematological malignanciesMauro Passucci, Chiara Masucci, Francesca Paoletti, et al.
Nuclear Medicine and Molecular Imaging|October 22, 2020
Acute Promyelocytic Leukemia After Radium-223 Exposure for Prostate Cancer in a Chemotherapy-Naïve PatientSalvatore Perrone, Elettra Ortu La Barbera, Tiziana Ottone, et al.
European Journal of Haematology|February 9, 2024
Neutrophil to lymphocyte ratio in myelofibrosis patients treated with ruxolitinib may predict prognosis and rate of discontinuationAlessandro Laganà, Mauro Passucci, Sara Pepe, et al.
Leukemia & Lymphoma|July 12, 2023
<i>CCND2</i> mutations in atypical chronic myeloid leukemia: a report of two casesGiovanni Iaquinta, Emilia Scalzulli, Silvia Angeloni, et al.
British Journal of Haematology|February 21, 2026
Prognostic impact of treatment-related and geriatric factors in older patients with classic Hodgkin lymphoma: A real-life cohort studySilvio Ligia, Giovanni Manfredi Assanto, Tania Soriano, et al.
Pageof 1